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EUROPEAN ERYTHEMA MIGRANS DISEASE
PLATE i. Erythema mi-
grans of at least six weeks'
duration with central lym-
phocytoma-like lesion in a
48-year-old woman. No tick
bite was noted.
PLATE ia. Spirochetallym-
phocytoma of eight weeks'
duration in a ten-year-old
girl. A tick bite occurred six
weeks prior to the begin-
ning of the lymphocytoma.
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PLATE m. Acrodermatitis
chronica atrophicans of one
year's duration in a 68-year-
old man. Note the marked
swelling and violaceous dis-
coloration of right hand and
arm.
PLATE iv. Acrodermatitis
chronica atrophicans oftwo
years' duration in a 77-year-
old woman. Note the vio-
laceous discoloration, infil-
tration, and atrophy of the
skin.
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European erythema migrans disease, lymphocytoma, and acrodermatitis chronica are a
group ofdisorders associated with the bite of ixodid ticks. These disorders are now thought to
be due to a single, or closely related, ixodid tick spirochetes. European erythema migrans
disease closely resembles Lyme disease. Serological evaluation may help to separate spirochetal
lymphocytoma from other pseudolymphomas of nonspirochetal origin and from lymphoma.
Acrodermatitis chronica atrophicans, so far observed mainly in Europe, is presumably a late
manifestation of this group of spirochetal disorders.
ERYTHEMA MIGRANS DISEASE (EMD)
Erythema migrans following a tick bite was first described by the Swedish der-
matologist Afzelius in 1909 [1]. A few years later, Lipschutz from Vienna gave a
more detailed description ofanother case using thedesignation erythemachronicum
migrans [2]. In 1922, Garin and Bujadoux described a case of meningopolyneuritis
[3]. Several years later, Hellerstrom presented a case with meningitis or, morelikely,
meningoencephalitis [4]. In 1934, the German dentist Stadelmann included among
his six erythema migrans patients the case of a patient with severe joint pain,
myalgia, and fatigue [5]. A detailed description ofmeningopolyneuritis wasgiven by
Bannwarth in the early 1940s [6]. In 1951, Hollstrom observed the beneficial effects
of penicillin for both erythema migrans and a patient with meningitis [7]. Binder et
al. reported the successful transmission oferythema migrans from human to human
four years later [8]. In the 1960s and early 1970s, erythema migrans was recognized
as a systemic disease by Hauser and others ([9]; literature in [19]). Horstrup and
Ackermann published a well-defined retrospective study on meningopolyneuritis in
1973 [10]. One year later, a case report showed that low doses of penicillin cleared
the erythema migrans but were not sufficient to prevent meningitis; a beneficial ef-
fect of high doses of parenteral penicillin was achieved in this patient. In the same
paper, it was concluded that a hitherto unknown bacterium must be the cause of
both erythema migrans and "erythema chronicum migrans meningitis" [11].
The description byAllen Steere and co-workers ofadisease which they first called
Lyme arthritis [12] has stimulated further work in Europe. One and a half years
before the discovery ofthe causative organism, high doses ofparenteral penicillin or
another appropriate antibiotic were suggested for later manifestations ofboth Lyme
disease and erythema migrans disease and for some patients with early manifesta-
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All rights of reproduction in any form reserved.tions of these disorders [13]. A turning point in the history of EMD and related
disorders was the discovery by Burgdorfer and co-workers of a spirochete from ixo-
did ticks, cultivation of the spirochetes, elicitation of animal lesions, and positive
serological reactions in patients with Lyme disease [14]. Recovery of spirochetes
from patients with Lyme disease was reported by Steere et al. and Benach et al. a few
months ago [15,16]. Ackermann, using Borreliae, and other spirochetes, and
Neubert, using rodent blood spirochetes supplied by Dr. H.E. Krampitz, obtained
positive serological reactions at the same time [17,18]. Soon afterwards, we de-
scribed 31 patients with what we now call erythema migrans disease [19]. The
serological evaluation of 42 patients was presented very recently [20].
European erythema migrans usually presents as an expanding annular lesion often
accompanied by central clearing. This lesion is the hallmark of the disease.
Sometimes, a central lymphocytoma-like lesion can also be seen [9,19] (PLATE I).
Erythema migrans can disappear after a short duration of up to four weeks; it can
exist in its chronic form as erythema chronicum migrans, or it may be absent [19].
European erythema migrans may be accompanied by general symptoms such as
headaches, fever and/or fatigue, arthritis or arthralgia, certain neurological find-
ings, probable cardiac involvement, and possibly tracheolaryngitis [19].
To date, we have observed 49 patients; 41 of them have been followed prospec-
tively since December 1978. In our study, 17 patients (35 percent) had joint symp-
toms; most had involvement ofthe elbow, the knee, and/or the joints of the fingers.
All patients had pain on motion of joints, eight had swelling, and only one ex-
perienced redness. Joint symptoms were usually not intermittent. Nine patients (18
percent) had neurologic signs. Six showed clinical evidence of meningopolyneuritis,
four had severe headaches, and three were mildly encephalopathic. Seven women
(14 percent) had signs suggestive of cardiac involvement. Five experienced one to
several attacks of palpitations, one had episodes of substernal chest pain, and one
had bradycardia.
Laboratory findings in up to 37 of the 49 patients included a moderate elevation
of ESR in 32 percent of the patients (mean value, 16 mm/h), elevation ofIgM (13
percent; mean value 316 mg/dl), IgG (10 percent; 1,432 mg/dl), or IgA (3 percent;
394 mg/dl), slight increase of SGPT (19 percent; 26 U/1) or SGOT (6 percent; 21
U/1), and mild cryoglobulinemia in one patient (12.6 mg/dl).
Forty-two patients were evaluated serologically [20]. We found IgG and/orIgM
antibody titers against Ixodes dammini spirochetes (kindly supplied by Dr.
Burgdorfer) to be significantly elevated in only 40 percent of our patients (Table 1).
Treatment in these patients was begun a mean of eight weeks (0.5-26) after the tick
bite or the beginning of the erythema migrans. The highest antibody titers were
detected in some patients with more severe disease. Thus, it is possible that antibiotic
therapy aborted the antibody response in some patients or that the disease was too
mild to allow for significant rise in antibody titer. Seven patients with EMD, three
with acrodermatitis chronica atrophicans (ACA), and two with lymphocytoma were
also tested at the Rocky Mountain Laboratory for IgG antibodies against both the
Ixodes dammini and the Swiss Ixodes ricinus spirochete. There was no significant
difference in the titers between these spirochetes, and the results were basically com-
parable to those obtained by the Max von Pettenkofer-Institut in Munich [20].
LYMPHOCYTOMA (LYMPHADENOSIS BENIGNA CUTIS)
The first description of a solitary cutaneous lesion with follicles resembling those
seen in lymph nodes was published by the Swiss pathologist Burckhardt in 1911 [21].
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TABLE 1
Significantly Elevated Antibody Titers by Indirect Immunofluorescence Test in Patients
with EMD, ACA, and Spirochetal Lymphocytoma Compared to Controls
Antibody Titers Against Ixodid Tick Spirochetes
IgG IgM
Absorbed Absorbed
with with
T. T.
Number of Unabsorbed phagedenis Unabsorbed phagedenis
Diagnosis Patients (%) 256 (%) .64 (%) >64 (%) 264 (%)
EMD 42 (100) 7 (17) 11 (26) 19 (45) 14 (33)
ACA 9 (100) 9 (100) 9 (100) 6 (67)a 5 (56)a
Lymphocytoma 4 (100) 2 (50) 3 (75) 3 (75) 1 (25)
Healthy controls 40 (100) 1 (2.5) 1 (2.5) 1 (2.5) 1 (2.5)
aIgM fraction negative
He clearly separated his case fromtruelymphoma. Theterm lymphadenosis benigna
cutis was introduced by Bafverstedt in 1943 [22]. Seven years later, Bianchi noticed
the beneficial effect of penicillin [23]. In 1957, Paschoud succeeded in transmitting
lymphocytoma from human to human [24]. Braun-Falco and Burg noted the
polyclonality of the lymphocytes within the lymphocytoma [25]. Histological
[26,27], enzyme cytochemical [25,27], immunocytological [25,27-29] andultrastruc-
tural [29,30] studies have provided more insight into our understanding of lym-
phocytoma and its differentiation from lymphoma in recent years. We recently
reported a serological evaluation of patients with lymphocytoma [20].
Lymphocytoma occurs most often as a solitary lesion but several grouped or even
more widespread lesions can sometimes be seen. Its size varies from a small nodule
to rather large plaques several centimeters in diameter. The red or violaceous lesions
have a firm consistency and are sometimes sensitive to touch (PLATE ii). The
histological diagnosis of lymphocytoma is aided by the follicular arrangement [31].
Such a follicle consists of small lymphocytes and central larger cells some of which
represent centrocytes or centroblasts such as are found in true lymph nodes [27].
Unlike lymphoma, B and T lymphocytes are present in lymphocytoma [25,27-29].
Macrophages are present in follicular and non-follicular structures, and a few
plasma cells and eosinophils may also be seen [25-27,31]. Electron microscopic
studies have revealed the presence of various lymphoid and reticulum cells with
many cytoplasmic processes [Weber K: unpublished two cases, 1974; 29,30].
The clinical features and laboratory findings ofwhat we now call spirochetal lym-
phocytoma are exemplified by the findings in our four patients. All had their lesions
on the ear; two-thirds of lymphocytomas are found on the head [9]. Our patients
had their lesions for a mean ofnine (6-12) weeks. However, ifuntreated, the lesions
may last months and even years. Although our patients had regional lym-
phadenopathy, general symptoms were absent except for occasional headaches in
two. However, meningitis has been reported [32], and a six-year-old boy had six
erythema migrans lesions for four weeks. We observed elevations of alpha2
globulins in all four patients, betaglobulin, in one, and IgM, in another patient (322
mg/dl). Serological examination of our patients revealed that they had a signifi-
cantly elevated titer of either IgG or IgM antibodies against ixodid tick spirochetes
[20] (Table 1). Thus, spirochetal lymphocytoma may now be diagnosed serologically.
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This condition was first described by the German physician Alfred Buchwald 100
years ago [33]. In 1902, Herxheimer and Hartmann introduced the designation ACA
[34]. Jessner described apatient with arthralgia and biopsy-proven laryngitis in 1921
and, three years later, together with Loewenstamm, mentioned 66 patients, nine of
whom had joint and bone involvement [35,36]. Soon afterward, Ehrmann and
Falkenstein suggested an infectious etiology [37]. In 1942, Kahle reported positive
pallida reactions in six out of seven patients; the pallida antigen used was a protein
fraction of Treponema phagedenis [38]. Two cases were successfully treated with
penicillin by Nanna Svartz in Sweden in 1946 [39]. Three years later, Thyresson
reported on the successful therapy of 57 cases [40]. Tetracycline, chloramphenicol,
erythromycin, and streptomycin were also found to be effective [41-43]. Gruneberg,
referring to the report ofKahle, performed pallida reactions in 104 patients, almost
10 percent ofwhom gave positive results compared to 0.6 percent ofthe controls; he
suspected a group-specific reaction due to a special ACA spirochete [44]. In 1954,
Gotz reported on the successful transmission of ACA from human to human [45].
Walter Hauser introduced the concept ofACA as ageneralized disease. Heobserved
regional lymphadenopathy, reactive hyperplasia in the bone marrow, and elec-
trophoretic changes. Many of his patients gave a history of tick bite, and he found
the geographical distribution of ACA to be concordant with the distribution of Ix-
odes ricinus. He was also impressed by the relationship among ACA, erythema
migrans, and lymphocytoma [46]. Several cases have been described with both ACA
and erythema migrans or erythema migrans-like lesions [43,45,46] and with ACA
and lymphocytoma [46]. In addition, in some patients ACA has been found to
follow erythema migrans [46,47], and lymphocytoma [48]. Peripheral neuropathy
was established as a manifestation of ACA by Hopf in 1966 (cited in [49]). Cryo-
globulinemia and changes in the immunoelectrophoresis have been observed in some
patients [50-52]. Among the malignancies associated with ACA, monoclonal gam-
mopathy ofWaldenstrom and lymphoma seem to be most remarkable [53,54]. Very
recently, we reported the serological findings in six patients [20].
ACA is achronic disorder usually with characteristic skin lesions [9,55,56]. In the
initial stage, the patient has violaceous discoloration and infiltration of the skin,
sometimes associated with marked swelling (PLATE III); in the atrophic stage, the skin
becomes thin and shows loss of appendages (PLATE iv). The lesions usually spread
from distal to proximal sites. In some instances, one finds periarticular fibrous
nodules and pseudosclerodermiform plaques or bands. Regional lymphadenopathy
is common [9,46]. Some patients have peripheral neuropathy [49]. There have been
several reports demonstrating joint and bone involvement [35,36,45,55]. Some-
times, patients experience arthralgia before and together with the appearance of the
skin lesions; the joint involvement may lead to severe impairment ofjoint function
[36,57]. Hovelborn believed that the same process which caused the skin involve-
ment also affected the joints [57].
Systemic symptoms are usually lacking, but three of our nine patients had symp-
toms such as fatigue, sensitivity to cold, cough, rhinorrhea, irritability, abdominal
pain, and epistaxis during the illness. While skin involvement was present, three of
the patients experienced palpitations, dizziness, chest pain and/or syncope (one
episode in one patient). Five ofthepatients had ahistory oftick bite, but in none did
the bite directly precede the appearance ofthe skin lesions. All patients had skin in-
volvement of the limbs and three of the face. Fibrous nodules were present in three,
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regional lymphadenopathy in four, neuropathy in two, arthralgia in one, and a
history of erythema migrans in one patient.
Five ofnine patients had an elevated ESR (mean value: 31 mm/h); all patients had
changes of the protein electrophoresis; four patients had elevation of IgG (1,710
mg/dl) and/or IgM (329), one of IgA (480), and one patient had rheumatoid factor
activity without joint complaints. IgG antibody titers against the I. dammini
spirochete were more or less elevated, but specific IgM titers were insignificant if
only the 19S fraction was used or if IgG was first absorbed with an anti-IgG anti-
serum [20] (Table 1).
In summary, these observations indicate that a single or closelyrelated spirochetes
cause a disease with many possible manifestations. The illness may present in its
early forms as erythema migrans disease or spirochetal lymphocytoma or both and
may later go on to late erythema migrans disease or ACA. Thus, at least in some in-
stances, ACA is thought to be a late manifestation of erythema migrans disease
and/or spirochetal lymphocytoma. However, many patients with ACA seem to lack
a history of erythema migrans disease or spirochetal lymphocytoma.
THERAPY
We recommend penicillin or tetracycline in appropriate dosage for therapy of
European ixodid tick spirochetosis. Erythema migrans can recur after the injection
of small doses of penicillin, 300,000 to 600,000 U for two to five days [58,59]; the
later manifestations of EMD are not prevented by low doses of oral phenoxymethyl
penicillin, 400,000 to 600,000 U for eight to ten days [11,19], and ACA has de-
veloped despite injections of procaine penicillin, 300,000 U daily for two or three
days [59]. High doses of oral phenoxymethyl penicillin, 1.5 million U three times a
day for eight to twelve days, did not prevent arthralgias, but, to date, severe mani-
festations have not developed in 12 patients with EMD followed prospectively since
May 1982 [Weber K: unpublished data]. Intravenous penicillin G, 10 to 20 million U
daily for eight to 14 days, were found to be effective in a few EMD patients with
meningitis, meningopolyneuritis, and polyarthritis [11,19]. The favorable effect of
the tetracyclines, usually 500 mg three to four times a day for seven to ten days, has
been observed by many physicians, including ourselves.
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